A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
Summary
Third Opinion Trial Synopsis:
This study is testing a new treatment called RO7425781 on people who have a kind of cancer called r/r MM and who can't have other treatments. The study has two parts: Part 1 will give different doses of the treatment to see how much is safe, and Part 2 will give different doses to different people to see if the treatment works.
This study is testing a new treatment called RO7425781 on people who have a kind of cancer called r/r MM and who can't have other treatments. The study has two parts: Part 1 will give different doses of the treatment to see how much is safe, and Part 2 will give different doses to different people to see if the treatment works.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies. The study consists of two parts: dose-escalation of forimtamig (Part 1) and a randomized dose expansion of forimtamig (Part 2).
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies. The study consists of two parts: dose-escalation of forimtamig (Part 1) and a randomized dose expansion of forimtamig (Part 2).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: